MX2022006444A - Linfocitos t activados por bite ex vivo. - Google Patents
Linfocitos t activados por bite ex vivo.Info
- Publication number
- MX2022006444A MX2022006444A MX2022006444A MX2022006444A MX2022006444A MX 2022006444 A MX2022006444 A MX 2022006444A MX 2022006444 A MX2022006444 A MX 2022006444A MX 2022006444 A MX2022006444 A MX 2022006444A MX 2022006444 A MX2022006444 A MX 2022006444A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- methods
- cancer
- killing
- cell
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 230000022534 cell killing Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Abstract
La generación y la identificación de células efectoras inmunitarias muy eficaces en términos de actividad de destrucción de células diana se puede potenciar mediante la optimización de la proximidad entre una célula diana y una célula efectora inmunitaria. Los linfocitos T destructores del cáncer descritos en el presente documento pueden proporcionar terapias altamente eficaces para diversos tipos de cáncer, por ejemplo, cánceres sólidos, cánceres hematológicos y formas metastásicas de los mismos. En el presente documento, se proporcionan métodos ex vivo de generación de linfocitos T destructores del cáncer, composiciones que comprenden dichas células inmunitarias; métodos de uso de las células, métodos para seleccionar agentes óptimos para potenciar la actividad de destrucción de las células diana, métodos para seleccionar una célula inmunitaria optimizada y métodos de uso de este enfoque para evaluar la capacidad de respuesta del paciente a otras terapias contra el cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662321964P | 2016-04-13 | 2016-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006444A true MX2022006444A (es) | 2022-06-22 |
Family
ID=58669776
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012488A MX2018012488A (es) | 2016-04-13 | 2017-04-12 | Linfocitos t activados por bite ex vivo. |
MX2022006444A MX2022006444A (es) | 2016-04-13 | 2018-10-11 | Linfocitos t activados por bite ex vivo. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012488A MX2018012488A (es) | 2016-04-13 | 2017-04-12 | Linfocitos t activados por bite ex vivo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190218515A1 (es) |
EP (1) | EP3445391A1 (es) |
JP (2) | JP7038353B2 (es) |
KR (1) | KR20180133442A (es) |
CN (2) | CN109789195A (es) |
AU (2) | AU2017249698B2 (es) |
CA (1) | CA3020830A1 (es) |
IL (2) | IL262359B (es) |
MX (2) | MX2018012488A (es) |
SG (1) | SG11201808909WA (es) |
WO (1) | WO2017178572A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109477073B (zh) * | 2016-03-31 | 2024-04-12 | 来恩生物医药私人有限公司 | 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞 |
AU2018250641A1 (en) * | 2017-04-11 | 2019-10-31 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
WO2019077062A1 (en) * | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
JP2021505659A (ja) * | 2017-12-01 | 2021-02-18 | ソリシメド バイオファーマ インコーポレイテッド | 癌治療のためのtrpv6阻害剤および併用療法 |
JP2021511790A (ja) * | 2018-02-02 | 2021-05-13 | ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズWake Forest University Health Sciences | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
JP2021519072A (ja) * | 2018-03-27 | 2021-08-10 | システィミューン, インク.Systimmune, Inc. | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
SG11202101851WA (en) * | 2018-08-31 | 2021-03-30 | Invectys SA | Method to assess car functionality |
CN115916816A (zh) * | 2019-12-11 | 2023-04-04 | 库利南肿瘤股份有限公司 | 抗血清白蛋白抗体 |
US20230037815A1 (en) * | 2019-12-11 | 2023-02-09 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
KR102578480B1 (ko) | 2021-04-12 | 2023-09-14 | 메디젠 테라퓨틱스, 인코포레이티드 | 항원에 노출된 cd8 t 세포의 활성화 및 증식 방법 그리고 그에 의해 제조된 항암 활성이 강화된 cd8 t 세포 및 그의 용도 |
US20230313140A1 (en) * | 2022-04-04 | 2023-10-05 | St. Jude Children's Research Hospital, Inc. | Method for preparing t cells for adoptive t cell therapy |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
TR200003087T2 (tr) | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
JP4562286B2 (ja) | 1998-12-10 | 2010-10-13 | ブリストル−マイヤーズ スクウィブ カンパニー | 抗体模倣物および他の結合タンパク質のタンパク質骨格 |
CA2367212A1 (en) | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
WO2003015705A2 (en) * | 2001-08-17 | 2003-02-27 | Roger Williams Hospital | In situ immunization |
EP1474161A4 (en) | 2002-01-16 | 2005-06-29 | Zyomyx Inc | TRANSGENIC BINDING PROTEINS |
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
RU2484470C2 (ru) | 2006-03-10 | 2013-06-10 | Вивия Биотек С.Л. | Высокоскоростное устройство для подачи образцов |
EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
MX2011002252A (es) | 2008-08-25 | 2011-06-24 | Amplimmune Inc | Composiciones de antagonistas del pd-1 y metodos de uso. |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
ES2628219T3 (es) | 2009-05-19 | 2017-08-02 | Vivia Biotech S.L. | Métodos para proporcionar ensayos de medicina personalizada ex vivo para neoplasias hematológicas |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
EP2981281B1 (en) * | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2015126548A1 (en) * | 2014-02-21 | 2015-08-27 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
-
2017
- 2017-04-12 SG SG11201808909WA patent/SG11201808909WA/en unknown
- 2017-04-12 JP JP2018554093A patent/JP7038353B2/ja active Active
- 2017-04-12 EP EP17721339.4A patent/EP3445391A1/en active Pending
- 2017-04-12 MX MX2018012488A patent/MX2018012488A/es unknown
- 2017-04-12 CN CN201780035722.2A patent/CN109789195A/zh active Pending
- 2017-04-12 WO PCT/EP2017/058891 patent/WO2017178572A1/en active Application Filing
- 2017-04-12 US US16/093,867 patent/US20190218515A1/en active Pending
- 2017-04-12 AU AU2017249698A patent/AU2017249698B2/en active Active
- 2017-04-12 KR KR1020187031631A patent/KR20180133442A/ko unknown
- 2017-04-12 CN CN202311188005.7A patent/CN117327650A/zh active Pending
- 2017-04-12 CA CA3020830A patent/CA3020830A1/en active Pending
- 2017-04-12 IL IL262359A patent/IL262359B/en unknown
- 2017-04-12 IL IL295538A patent/IL295538B2/en unknown
-
2018
- 2018-10-11 MX MX2022006444A patent/MX2022006444A/es unknown
-
2022
- 2022-02-21 JP JP2022024946A patent/JP2022081509A/ja active Pending
-
2023
- 2023-06-09 AU AU2023203601A patent/AU2023203601A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3020830A1 (en) | 2017-10-19 |
AU2017249698B2 (en) | 2023-03-09 |
MX2018012488A (es) | 2019-06-06 |
US20190218515A1 (en) | 2019-07-18 |
IL262359B (en) | 2022-09-01 |
JP2019513400A (ja) | 2019-05-30 |
IL295538B2 (en) | 2024-02-01 |
AU2023203601A1 (en) | 2023-07-06 |
SG11201808909WA (en) | 2018-11-29 |
JP7038353B2 (ja) | 2022-03-18 |
JP2022081509A (ja) | 2022-05-31 |
IL295538A (en) | 2022-10-01 |
IL262359A (en) | 2018-11-29 |
IL295538B1 (en) | 2023-10-01 |
AU2017249698A1 (en) | 2018-11-08 |
CN109789195A (zh) | 2019-05-21 |
EP3445391A1 (en) | 2019-02-27 |
KR20180133442A (ko) | 2018-12-14 |
WO2017178572A1 (en) | 2017-10-19 |
CN117327650A (zh) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006444A (es) | Linfocitos t activados por bite ex vivo. | |
MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
GB2557123A (en) | Modified cells and methods of therapy | |
MX2022010490A (es) | Composiciones utiles para enzimas de internalizacion. | |
NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
MX2019008503A (es) | Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos. | |
GB2531952A (en) | SC-ß cells and compositions and methods for generating the same | |
MX2017004691A (es) | Bloqueo de cd73. | |
WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
MX2021003858A (es) | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. | |
NZ730563A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
MX2020010194A (es) | Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. | |
MY180894A (en) | Methods for incresing efficacy of folr1 cancer therapy | |
WO2015009726A3 (en) | Medical uses of cd38 agonists | |
NZ739133A (en) | Cellular targeted active ingredient delivery system | |
MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
WO2014164730A3 (en) | Modulation of cellular dna repair activity to intercept malignancy | |
PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
MX365392B (es) | Composición de combinación de pac-1 y doxorrubicina. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
EP3998341A3 (en) | Adenoviral vectors | |
AU2014249346A8 (en) | High purity ovarian cancer stem cells for active autologous immune therapy |